This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ménard, J. Articles by Kleinert, H. D. Search for Related Content PubMed PubMed Citation Articles by Ménard, J. Articles by Kleinert, H. D.

(Circulation. 1995;91:330-338.)
© 1995 American Heart Association, Inc.

Articles

Dose-Dependent Effects of the Renin Inhibitor Zankiren HCl After a Single Oral Dose in Mildly Sodium-Depleted Normotensive Subjects

Joël Ménard, MD; Robert S. Boger, MD; Denise M. Moyse, MS; Tam T. Guyene, MD; Harriet N. Glassman, MS; Hollis D. Kleinert, PhD

From the INSERM U367, Hospital Broussais, Paris, France (J.M., T.T.G.) and Abbott Laboratories, Abbott Park, Ill (R.S.B., D.M.M., H.N.G., H.D.K.).

Correspondence to Hollis D. Kleinert, PhD, Abbott Laboratories, Department 48G, Bldg AP9, 100 Abbott Park Rd, Abbott Park, IL 60064-3500.

Background Zankiren HCl (A-72517) is a potent renin inhibitor shown to have substantial bioavailability in several animal species and to produce dose-related reductions in blood pressure, plasma renin activity, and angiotensin II (Ang II) in salt-depleted dogs. The present study was designed to evaluate the hemodynamic effects of oral zankiren HCl administration in healthy volunteers and to characterize the response of the renin-angiotensin system (RAS) to specific blockade by this new renin inhibitor.

Methods and Results Twenty-four male volunteers participated in a double-blind randomized, placebo-controlled in-hospital study to evaluate the effects of zankiren HCl (10 to 250 mg). All subjects were pretreated with 40 mg furosemide 12 hours before study drug administration. Blood pressure and heart rate were monitored by an automated oscillometric device, and blood samples were obtained for active renin, total renin, plasma renin activity, angiotensin I (Ang I), Ang II, aldosterone, and plasma zankiren concentration. Satisfactory absorption of zankiren HCl was demonstrated by the results of plasma drug concentration determinations, and renin inhibitory activity was confirmed by dose-related suppression of plasma renin activity, Ang I, Ang II, and aldosterone and increases in plasma active renin concentration. Furthermore, hypotensive activity was readily observed in these normotensive subjects, as evidenced by statistically significant dose-related blood pressure reductions (P<.01).

Conclusions Results from this study demonstrate for the first time that oral administration of a renin inhibitor can dose-dependently decrease blood pressure and circulating components of the RAS in normotensive volunteers as a result of documented absorption.

Key Words: angiotensin • antihypertensive agents • blood pressure • hypertension

This article has been cited by other articles:

				M. Azizi, J. Menard, A. Bissery, T.-T. Guyenne, A. Bura-Riviere, S. Vaidyanathan, and R. P. Camisasca Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3126 - 3133. [Abstract] [Full Text] [PDF]

				M. Azizi, A. Bissery, M. Lamarre-Cliche, and J. Menard Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans Hypertension, April 1, 2004; 43(4): 785 - 790. [Abstract] [Full Text] [PDF]

				M. Azizi, G. Chatellier, T.-T. Guyene, D. Murieta-Geoffroy, and J. Menard Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives Circulation, August 15, 1995; 92(4): 825 - 834. [Abstract] [Full Text]